- Home
- FHTX vs EDD Comparison
FHTX vs EDD Comparison
Compare FHTX & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- EDD
- Stock Information
- Founded
- FHTX 2015
- EDD 2007
- Country
- FHTX United States
- EDD United States
- Employees
- FHTX N/A
- EDD N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- EDD Finance Companies
- Sector
- FHTX Health Care
- EDD Finance
- Exchange
- FHTX Nasdaq
- EDD Nasdaq
- Market Cap
- FHTX 278.1M
- EDD 329.4M
- IPO Year
- FHTX 2020
- EDD N/A
- Fundamental
- Price
- FHTX $5.06
- EDD $5.30
- Analyst Decision
- FHTX Strong Buy
- EDD
- Analyst Count
- FHTX 6
- EDD 0
- Target Price
- FHTX $11.33
- EDD N/A
- AVG Volume (30 Days)
- FHTX 87.3K
- EDD 254.3K
- Earning Date
- FHTX 08-05-2025
- EDD 01-01-0001
- Dividend Yield
- FHTX N/A
- EDD 7.52%
- EPS Growth
- FHTX N/A
- EDD N/A
- EPS
- FHTX N/A
- EDD N/A
- Revenue
- FHTX $24,173,000.00
- EDD N/A
- Revenue This Year
- FHTX $43.75
- EDD N/A
- Revenue Next Year
- FHTX $1.27
- EDD N/A
- P/E Ratio
- FHTX N/A
- EDD N/A
- Revenue Growth
- FHTX N/A
- EDD N/A
- 52 Week Low
- FHTX $2.95
- EDD $4.22
- 52 Week High
- FHTX $10.25
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- FHTX 47.33
- EDD 56.10
- Support Level
- FHTX $5.16
- EDD $5.24
- Resistance Level
- FHTX $5.63
- EDD $5.42
- Average True Range (ATR)
- FHTX 0.35
- EDD 0.05
- MACD
- FHTX 0.01
- EDD -0.01
- Stochastic Oscillator
- FHTX 38.83
- EDD 40.00
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.